210 reports of this reaction
1.5% of all DESONIDE reports
#17 most reported adverse reaction
DERMATITIS ATOPIC is the #17 most commonly reported adverse reaction for DESONIDE, manufactured by Actavis Pharma, Inc.. There are 210 FDA adverse event reports linking DESONIDE to DERMATITIS ATOPIC. This represents approximately 1.5% of all 14,012 adverse event reports for this drug.
Patients taking DESONIDE who experience dermatitis atopic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ATOPIC is a less commonly reported adverse event for DESONIDE, but still significant enough to appear in the safety profile.
In addition to dermatitis atopic, the following adverse reactions have been reported for DESONIDE:
The following drugs have also been linked to dermatitis atopic in FDA adverse event reports:
DERMATITIS ATOPIC has been reported as an adverse event in 210 FDA reports for DESONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ATOPIC accounts for approximately 1.5% of all adverse event reports for DESONIDE, making it a notable side effect.
If you experience dermatitis atopic while taking DESONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.